Alnylam Pharmaceuticals Inc.

Company Overview

Alnylam Pharmaceuticals, Inc. is a global biopharmaceutical company commercializing innovative therapies leveraging ribonucleic acid interference RNAi technology. The company mentions the transformative potential of this groundbreaking approach to revolutionize patient care, both for rare and common diseases.

Alnylam has received approval for five pioneering RNAi-based medications: Onpattro (patisiran), Amvuttra (vutrisiran), Givlaari (givosiran), Oxlumo (lumasiran), and Leqvio (inclisiran). Their research and development strategy centers on targeting genetically validated genes associated with the etiology or pathways of human diseases. We employ two primary delivery methods: N-acetylgalactosamine (GalNAc) conjugates or lipid nanoparticles (LNPs) to facilitate the delivery of siRNAs to the liver. Throughout 2023, the company continued to refine its approaches for delivering siRNAs to the heart, skeletal muscle, and adipose tissue. In early 2021, Alnylam introduced the P x25 strategy, which aimed to propel it to the forefront of the biotech industry by the end of 2025.
 
Based on their expertise in RNAi therapeutics and broad intellectual property estate, Alnylam entered into formed collaboration agreements with top pharmaceutical and life sciences companies to establish development and commercialization efforts, including Regeneron, Roche, Novartis (which acquired Alnylam’s collaborator The Medicines Company, or MDCO, in 2020), Sanofi, Vir Biotechnology, Inc., or Vir, Dicerna Pharmaceuticals, Inc. (acquired by Novo Nordisk, in December 2021), or Dicerna, and PeptiDream, Inc.,

Financial Highlights (FY 2023)

Company's Business Segments

• Product Revenues : ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO.
• Revenues from collaborations : Roche, Regeneron Pharmaceuticals, Novartis AG, Other.
• Royalty revenue : Royalties earned from global net sales of Leqvio by the company's collaborator, Novartis.